BioMarin to acquire Dimerix US Partner, Amicus Therapeutics
Filed with ASX · · 4 pages · English
• BioMarin has entered into a definitive agreement to acquire Dimerix’s US commercial licensing partner, Amicus, for a total equity value of approximately US$4.8 billion (~AU$7.25 billion1) • Subject to the transaction completing, BioMarin’s acquisition will include the Dimerix commercial licensing contract, including all rights and obligations currently held by Amicus MELBOURNE, Australia, 22 Dec
Story so far
Earlier from Dimerix
- DMX-200 ACTION3 Phase 3 trial completes recruitment
- Successful Completion of Planned IDMC Review
- Successful PARASOL Collaboration Data Analysis Outcome
- DMX-200 receives Orphan Drug Designation in Japan
- Appendix 4E and 2025 Annual Report
Later from Dimerix
- Quarterly Appendix 4C and Activities Report
- Appendix 4D and Half Year Financial Report
- Dimerix Phase 3 Trial Last Patient Receives First Dose
- Dimerix to Conduct Review of ACTION3 Statistical Assumptions
- ACTION3 Statistical Review Complete
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix